🔊CEOInterviews

Stephen Rusckowski on pandemic response

From COVID-19 testing volume has 'come down,' Quest Diagnostics CEO says · · Yahoo Finance

“We have now about 300,000 test capacity per day. We've been at a fraction of that for the last several weeks. We actually have seen the testing volume for what's referred to as PCR of sexual lab testing capability for Copic come down, but we're prepared in the event that it starts to ramp up. They'll be able to bring on more tests, so we're not closing down that capacity, but we're prepared in the event that it comes back up.”

Stephen Rusckowski
Former Chairman, President & Chief Executive Officer, Quest Diagnostics
pandemic responsetesting capacityoperational flexibility

On , Stephen Rusckowski, Former Chairman, President & Chief Executive Officer at Quest Diagnostics, spoke about pandemic response during COVID-19 testing volume has 'come down,' Quest Diagnostics CEO says on Yahoo Finance.

COVID-19 testing volume has 'come down,' Quest Diagnostics CEO says
Watch on YouTube at 2:03
COVID-19 testing volume has 'come down,' Quest Diagnostics CEO says
Yahoo Finance
Watch on YouTube at 2:03
COVID-19 #coronavirus #yahoofinance Quest Diagnostics CEO Steve Rusckowski joins Yahoo Finance Live to discuss the state ...
Stephen Rusckowski

About Stephen Rusckowski

Former Chairman, President & Chief Executive Officer · Quest Diagnostics

In a January 2023 interview, Rusckowski stated that Quest Diagnostics' COVID-19 testing volume had "come down" from its peak, though the company remained prepared for a potential increase. He described the prior decade as "remarkable," citing the Affordable Care Act, Medicare payment cuts, and the pandemic as major changes in healthcare delivery. Rusckowski noted that Quest Diagnostics represents "about two percent of health care costs in this country" but provides "about 75 percent of the information" used in clinical decision-making. He also said the company had "bent the cost curve" for its own employees, with 95 percent seeing no increase in healthcare payments. In a July 2021 interview, Rusckowski reported that Quest Diagnostics' COVID-19 testing revenue was "considerable" in 2020, exceeding $2 billion, and that testing volume had declined in the first half of 2021 before a slight increase linked to the delta variant. He stated that the majority of the company's positive COVID-19 tests at that time were delta variants, identified through next-generation sequencing provided to the CDC. Rusckowski also said the company was working to improve serology tests to distinguish between antibodies from vaccination and natural infection.

Profile compiled from Stephen Rusckowski's verified public interviews and appearances. See all quotes & transcripts →

More from Stephen Rusckowski Quest Diagnostics (DGX) Full Transcript Explore All Executives